Chargement en cours...
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo()
KP1339 is a promising ruthenium-based anticancer compound in early clinical development. This study aimed to test the effects of KP1339 on the in vitro and in vivo activity of the multi-kinase inhibitor sorafenib, the current standard first-line therapy for advanced hepatoma. Anticancer activity of...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier Science Ltd
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3807657/ https://ncbi.nlm.nih.gov/pubmed/23790465 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2013.05.018 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|